Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
Authors:
- 31 January 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (3) , 691-698
Abstract
Purpose: The therapeutic choice for patients with lung adenocarcinoma depends on the presence of EGF receptor (EGFR) mutations. In many cases, only cytologic samples are available for molecular diagnosis. Bronchoalveolar lavage (BAL) and pleural fluid, which represent a considerable proportion of cytologic specimens, cannot always be used for molecular testing because of low rate of tumor cells. Experimental Design: We tested the feasibility of EGFR mutation analysis on BAL and pleural fluid samples by next-generation sequencing (NGS), an innovative and extremely sensitive platform. The study was devised to extend the EGFR test to those patients who could not get it due to the paucity of biologic material. A series of 830 lung cytology specimens was used to select 48 samples (BAL and pleural fluid) from patients with EGFR mutations in resected tumors. These samples included 36 cases with 0.3% to 9% of neoplastic cells (series A) and 12 cases without evidence of tumor (series B). All samples were analyzed by Sanger sequencing and NGS on 454 Roche platform. A mean of 21,130 ± 2,370 sequences per sample were obtained by NGS. Results: In series A, EGFR mutations were detected in 16% of cases by Sanger sequencing and in 81% of cases by NGS. Seventy-seven percent of cases found to be negative by Sanger sequencing showed mutations by NGS. In series B, all samples were negative for EGFR mutation by Sanger sequencing whereas 42% of them were positive by NGS. Conclusions: The very sensitive EGFR-NGS assay may open up to the possibility of specific treatments for patients otherwise doomed to re-biopsies or nontargeted therapies. Clin Cancer Res; 19(3); 691–8. ©2012 AACR.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical ImplicationsPLOS ONE, 2012
- EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with ChemotherapyJournal of Thoracic Oncology, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?The Lancet Oncology, 2011
- Benchmarking of Mutation Diagnostics in Clinical Lung Cancer SpecimensPLOS ONE, 2011
- Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCRPLOS ONE, 2011
- Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular TestingJournal of Thoracic Oncology, 2011
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European WorkshopJournal of Thoracic Oncology, 2010
- Next-Generation DNA Sequencing MethodsAnnual Review of Genomics and Human Genetics, 2008
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencingNature Medicine, 2006